Tempest Therapeutics, Inc. Cash and Restricted Cash
Tempest Therapeutics, Inc. (TPST) had Cash and Restricted Cash of $1.22 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.22M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.25M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.15M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.96M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $1.22M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.25M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $8.15M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $7.96M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $14.72M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $21.95M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $30.71M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $22.91M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $31.57M 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $32.77M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $39.67M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $11.51M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $17.97M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $23.29M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $31.60M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $43.16M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $51.99M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $46.12M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $51.83M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $59.76M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $68.46M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $27.44M 10-Q · filed 2022-05-13 | $26.85M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $18.82M 10-K · filed 2023-03-22 | $38.66M 10-K · filed 2021-03-29 |
| 2020-09-30 | $23.07M 10-Q · filed 2021-11-10 | $43.75M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $27.69M 10-Q · filed 2021-08-12 | $51.02M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $58.88M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $3.24M 10-K · filed 2022-03-29 | $63.51M 10-K · filed 2020-03-11 |
| 2019-09-30 | $48.35M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $56.63M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $66.07M 10-Q · filed 2020-05-08 | |
| 2018-12-31 | $73.77M 10-K · filed 2021-03-29 | |
| 2018-09-30 | $9.77M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $6.82M 10-Q · filed 2019-08-12 | |
| 2018-03-31 | $12.09M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $17.62M 10-K · filed 2020-03-11 | |
| 2016-12-31 | $41.95M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |